| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mesothelioma | 101 | 2025 | 148 | 24.070 |
Why?
|
| Lung Neoplasms | 34 | 2026 | 495 | 9.880 |
Why?
|
| Ubiquitin Thiolesterase | 25 | 2025 | 57 | 8.550 |
Why?
|
| Asbestos | 42 | 2024 | 57 | 8.440 |
Why?
|
| Tumor Suppressor Proteins | 27 | 2025 | 223 | 8.030 |
Why?
|
| Pleural Neoplasms | 43 | 2020 | 57 | 7.600 |
Why?
|
| Germ-Line Mutation | 12 | 2025 | 75 | 4.040 |
Why?
|
| Simian virus 40 | 20 | 2011 | 35 | 3.370 |
Why?
|
| HMGB1 Protein | 11 | 2023 | 30 | 3.140 |
Why?
|
| Genetic Predisposition to Disease | 13 | 2024 | 734 | 3.130 |
Why?
|
| Melanoma | 8 | 2022 | 110 | 2.730 |
Why?
|
| Occupational Exposure | 11 | 2023 | 91 | 2.550 |
Why?
|
| Environmental Exposure | 12 | 2016 | 256 | 2.260 |
Why?
|
| Skin Neoplasms | 6 | 2022 | 178 | 2.110 |
Why?
|
| Cell Transformation, Neoplastic | 10 | 2020 | 165 | 2.040 |
Why?
|
| Humans | 128 | 2026 | 43102 | 1.810 |
Why?
|
| Zeolites | 7 | 2015 | 9 | 1.780 |
Why?
|
| Uveal Neoplasms | 4 | 2020 | 11 | 1.590 |
Why?
|
| Coronavirus | 2 | 2021 | 9 | 1.310 |
Why?
|
| Neoplasms | 9 | 2024 | 1377 | 1.300 |
Why?
|
| Mutation | 8 | 2023 | 1177 | 1.250 |
Why?
|
| Epithelium | 9 | 2017 | 78 | 1.190 |
Why?
|
| Prognosis | 15 | 2026 | 861 | 1.190 |
Why?
|
| Asbestosis | 4 | 2020 | 7 | 1.160 |
Why?
|
| Inhalation Exposure | 3 | 2019 | 44 | 1.060 |
Why?
|
| Carcinogens | 9 | 2015 | 126 | 1.000 |
Why?
|
| Thoracic Neoplasms | 1 | 2026 | 2 | 0.960 |
Why?
|
| Immunotherapy | 5 | 2018 | 144 | 0.930 |
Why?
|
| Calcium Signaling | 2 | 2024 | 107 | 0.930 |
Why?
|
| Apoptosis | 11 | 2024 | 1568 | 0.920 |
Why?
|
| Ovarian Neoplasms | 3 | 2019 | 415 | 0.910 |
Why?
|
| Heterozygote | 5 | 2025 | 110 | 0.890 |
Why?
|
| Tumor Virus Infections | 9 | 2011 | 22 | 0.850 |
Why?
|
| Arsenic | 2 | 2023 | 155 | 0.830 |
Why?
|
| Female | 42 | 2025 | 24698 | 0.820 |
Why?
|
| Water Pollutants, Chemical | 2 | 2023 | 171 | 0.820 |
Why?
|
| Peritoneal Neoplasms | 5 | 2016 | 18 | 0.810 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2024 | 91 | 0.800 |
Why?
|
| Mitochondria | 2 | 2017 | 523 | 0.800 |
Why?
|
| Incidence | 8 | 2023 | 1078 | 0.790 |
Why?
|
| Stearoyl-CoA Desaturase | 2 | 2019 | 5 | 0.780 |
Why?
|
| Cell Nucleus | 4 | 2021 | 383 | 0.770 |
Why?
|
| DNA Repair | 1 | 2024 | 198 | 0.770 |
Why?
|
| Polyomavirus Infections | 7 | 2011 | 18 | 0.740 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2023 | 88 | 0.730 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2023 | 384 | 0.730 |
Why?
|
| Male | 38 | 2025 | 23409 | 0.720 |
Why?
|
| Histone Deacetylase 1 | 1 | 2021 | 16 | 0.720 |
Why?
|
| Nasopharynx | 1 | 2021 | 6 | 0.710 |
Why?
|
| Middle Aged | 27 | 2025 | 12222 | 0.710 |
Why?
|
| Aged | 26 | 2025 | 8214 | 0.700 |
Why?
|
| Delayed Diagnosis | 1 | 2021 | 38 | 0.690 |
Why?
|
| Pneumonectomy | 2 | 2019 | 10 | 0.680 |
Why?
|
| Animals | 37 | 2024 | 16992 | 0.670 |
Why?
|
| RecQ Helicases | 1 | 2020 | 35 | 0.650 |
Why?
|
| Communicable Diseases | 1 | 2021 | 47 | 0.650 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2015 | 32 | 0.640 |
Why?
|
| Cell Death | 6 | 2023 | 278 | 0.640 |
Why?
|
| Asbestos, Crocidolite | 5 | 2020 | 8 | 0.620 |
Why?
|
| Kidney Neoplasms | 1 | 2020 | 80 | 0.610 |
Why?
|
| Pneumonia | 1 | 2020 | 61 | 0.600 |
Why?
|
| Inflammation | 5 | 2023 | 758 | 0.600 |
Why?
|
| Mice | 20 | 2024 | 6644 | 0.570 |
Why?
|
| Pedigree | 5 | 2025 | 94 | 0.570 |
Why?
|
| Cullin Proteins | 2 | 2015 | 12 | 0.560 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 83 | 0.560 |
Why?
|
| Neurofibromin 2 | 2 | 2015 | 6 | 0.560 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 88 | 0.560 |
Why?
|
| Immunohistochemistry | 12 | 2016 | 934 | 0.550 |
Why?
|
| Cell Movement | 6 | 2024 | 655 | 0.530 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 2017 | 10 | 0.530 |
Why?
|
| Signal Transduction | 6 | 2020 | 2157 | 0.510 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2016 | 11 | 0.510 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2016 | 15 | 0.510 |
Why?
|
| Cytoplasm | 1 | 2017 | 154 | 0.510 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2016 | 154 | 0.510 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2015 | 34 | 0.500 |
Why?
|
| Endoplasmic Reticulum | 1 | 2017 | 108 | 0.500 |
Why?
|
| Chromosome Deletion | 1 | 2016 | 53 | 0.500 |
Why?
|
| Repressor Proteins | 4 | 2018 | 273 | 0.500 |
Why?
|
| Cancer Vaccines | 2 | 2015 | 30 | 0.500 |
Why?
|
| Mixed Tumor, Malignant | 1 | 2016 | 1 | 0.490 |
Why?
|
| Mixed Tumor, Mullerian | 1 | 2016 | 1 | 0.490 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2016 | 6 | 0.490 |
Why?
|
| Neoplasms, Second Primary | 2 | 2014 | 15 | 0.490 |
Why?
|
| Dysplastic Nevus Syndrome | 1 | 2015 | 2 | 0.480 |
Why?
|
| DNA, Neoplasm | 2 | 2015 | 92 | 0.470 |
Why?
|
| Uterine Neoplasms | 1 | 2016 | 53 | 0.450 |
Why?
|
| Iron | 2 | 2022 | 251 | 0.440 |
Why?
|
| Particulate Matter | 1 | 2015 | 83 | 0.440 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 133 | 0.430 |
Why?
|
| Epithelial Cells | 5 | 2020 | 434 | 0.430 |
Why?
|
| Membrane Proteins | 2 | 2012 | 561 | 0.430 |
Why?
|
| Calcium | 1 | 2017 | 491 | 0.430 |
Why?
|
| Aged, 80 and over | 12 | 2025 | 2853 | 0.420 |
Why?
|
| Asbestos, Serpentine | 1 | 2013 | 2 | 0.420 |
Why?
|
| Gene Silencing | 3 | 2016 | 154 | 0.410 |
Why?
|
| Environmental Monitoring | 3 | 2024 | 230 | 0.400 |
Why?
|
| Hazardous Substances | 1 | 2013 | 19 | 0.400 |
Why?
|
| Cell Line, Tumor | 15 | 2024 | 2676 | 0.400 |
Why?
|
| Turkey | 6 | 2015 | 23 | 0.390 |
Why?
|
| Antibodies, Monoclonal | 2 | 2012 | 306 | 0.380 |
Why?
|
| Genomic Instability | 2 | 2024 | 37 | 0.380 |
Why?
|
| United States | 9 | 2022 | 5205 | 0.380 |
Why?
|
| Cell Proliferation | 7 | 2024 | 1455 | 0.370 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2017 | 968 | 0.360 |
Why?
|
| Cells, Cultured | 9 | 2020 | 1621 | 0.360 |
Why?
|
| Adult | 16 | 2025 | 13872 | 0.340 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2009 | 245 | 0.310 |
Why?
|
| Lymphangioleiomyomatosis | 1 | 2009 | 5 | 0.310 |
Why?
|
| Diagnosis, Differential | 6 | 2019 | 238 | 0.310 |
Why?
|
| Fibroblasts | 2 | 2024 | 281 | 0.310 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2024 | 220 | 0.300 |
Why?
|
| Ubiquitin | 2 | 2021 | 81 | 0.300 |
Why?
|
| Reproducibility of Results | 5 | 2020 | 1081 | 0.290 |
Why?
|
| DNA, Viral | 3 | 2011 | 311 | 0.280 |
Why?
|
| Biopsy | 3 | 2016 | 177 | 0.280 |
Why?
|
| Neoplasm Staging | 8 | 2017 | 374 | 0.260 |
Why?
|
| Brain Neoplasms | 2 | 2011 | 140 | 0.250 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2021 | 652 | 0.250 |
Why?
|
| China | 2 | 2017 | 229 | 0.250 |
Why?
|
| Antibodies, Neoplasm | 1 | 2006 | 20 | 0.250 |
Why?
|
| Environmental Pollutants | 1 | 2009 | 201 | 0.240 |
Why?
|
| Protein Binding | 2 | 2021 | 1082 | 0.240 |
Why?
|
| Osteopontin | 4 | 2016 | 46 | 0.240 |
Why?
|
| Alleles | 3 | 2016 | 352 | 0.240 |
Why?
|
| Mice, Inbred BALB C | 5 | 2017 | 694 | 0.230 |
Why?
|
| DNA Damage | 2 | 2018 | 356 | 0.230 |
Why?
|
| Cohort Studies | 5 | 2014 | 1759 | 0.230 |
Why?
|
| Leukemia, Prolymphocytic | 1 | 2005 | 1 | 0.230 |
Why?
|
| Vidarabine | 1 | 2005 | 2 | 0.230 |
Why?
|
| Pleura | 2 | 2019 | 5 | 0.220 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 3 | 2011 | 108 | 0.220 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 3 | 2011 | 105 | 0.220 |
Why?
|
| Keratins | 1 | 2004 | 26 | 0.220 |
Why?
|
| Sex Factors | 3 | 2016 | 1028 | 0.220 |
Why?
|
| Sarcoma | 1 | 2004 | 11 | 0.220 |
Why?
|
| Fructose | 1 | 2024 | 24 | 0.220 |
Why?
|
| Genome, Human | 2 | 2016 | 144 | 0.220 |
Why?
|
| Aluminum Silicates | 1 | 2024 | 7 | 0.220 |
Why?
|
| Mining | 1 | 2024 | 19 | 0.210 |
Why?
|
| Mass Screening | 1 | 2009 | 541 | 0.210 |
Why?
|
| Tumor Cells, Cultured | 5 | 2017 | 508 | 0.210 |
Why?
|
| RNA, Messenger | 5 | 2016 | 1271 | 0.200 |
Why?
|
| Europe | 2 | 2019 | 115 | 0.200 |
Why?
|
| NF-kappa B | 1 | 2006 | 358 | 0.200 |
Why?
|
| Cricetinae | 3 | 2010 | 241 | 0.200 |
Why?
|
| Age Factors | 3 | 2016 | 1154 | 0.200 |
Why?
|
| Neoplasm Invasiveness | 2 | 2016 | 290 | 0.200 |
Why?
|
| Risk Assessment | 5 | 2016 | 863 | 0.200 |
Why?
|
| Sarcoma, Synovial | 1 | 2002 | 2 | 0.190 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 173 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 6 | 2010 | 455 | 0.190 |
Why?
|
| Nevada | 3 | 2022 | 6 | 0.190 |
Why?
|
| Sensitivity and Specificity | 5 | 2016 | 611 | 0.190 |
Why?
|
| Soil Pollutants | 1 | 2024 | 105 | 0.190 |
Why?
|
| Caspases | 1 | 2023 | 148 | 0.190 |
Why?
|
| Gene Expression Profiling | 4 | 2013 | 704 | 0.190 |
Why?
|
| Soil | 1 | 2024 | 171 | 0.190 |
Why?
|
| Uranium | 1 | 2022 | 24 | 0.190 |
Why?
|
| Epigenesis, Genetic | 1 | 2025 | 291 | 0.190 |
Why?
|
| Phenotype | 1 | 2025 | 780 | 0.190 |
Why?
|
| Receptors, Cell Surface | 1 | 2003 | 146 | 0.180 |
Why?
|
| Poliovirus Vaccines | 1 | 2002 | 2 | 0.180 |
Why?
|
| SEER Program | 2 | 2014 | 164 | 0.180 |
Why?
|
| Macrophages | 2 | 2020 | 529 | 0.180 |
Why?
|
| Antineoplastic Agents | 4 | 2016 | 1019 | 0.180 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2021 | 6 | 0.180 |
Why?
|
| Telomerase | 1 | 2002 | 42 | 0.180 |
Why?
|
| Fatal Outcome | 1 | 2021 | 48 | 0.180 |
Why?
|
| Doxorubicin | 3 | 2010 | 97 | 0.180 |
Why?
|
| Administration, Inhalation | 1 | 2021 | 92 | 0.170 |
Why?
|
| Case-Control Studies | 6 | 2016 | 1285 | 0.170 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 64 | 0.170 |
Why?
|
| Endotoxemia | 1 | 2020 | 5 | 0.170 |
Why?
|
| Cell Line, Transformed | 3 | 2008 | 95 | 0.170 |
Why?
|
| Computers | 1 | 2020 | 35 | 0.160 |
Why?
|
| Extracellular Matrix Proteins | 3 | 2020 | 78 | 0.160 |
Why?
|
| Adenocarcinoma | 2 | 2020 | 291 | 0.160 |
Why?
|
| Young Adult | 6 | 2016 | 5080 | 0.160 |
Why?
|
| Follow-Up Studies | 4 | 2016 | 1067 | 0.150 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 21 | 0.150 |
Why?
|
| Cell Transformation, Viral | 2 | 2011 | 24 | 0.150 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2005 | 61 | 0.150 |
Why?
|
| International Cooperation | 1 | 2019 | 52 | 0.150 |
Why?
|
| Family | 1 | 2020 | 195 | 0.150 |
Why?
|
| Autophagy | 1 | 2020 | 140 | 0.150 |
Why?
|
| Australia | 1 | 2019 | 103 | 0.150 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 167 | 0.150 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 259 | 0.150 |
Why?
|
| Pleural Effusion, Malignant | 3 | 2012 | 7 | 0.150 |
Why?
|
| Mesocricetus | 2 | 2010 | 56 | 0.150 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 112 | 0.140 |
Why?
|
| Toll-Like Receptors | 1 | 2018 | 51 | 0.140 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 61 | 0.140 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2017 | 347 | 0.140 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 148 | 0.140 |
Why?
|
| Transcription Factors | 1 | 2003 | 735 | 0.140 |
Why?
|
| Cocarcinogenesis | 2 | 2008 | 6 | 0.130 |
Why?
|
| Pyruvates | 1 | 2017 | 6 | 0.130 |
Why?
|
| Protein Stability | 1 | 2017 | 48 | 0.130 |
Why?
|
| Asthma | 1 | 2021 | 416 | 0.130 |
Why?
|
| Quality of Life | 1 | 2022 | 616 | 0.130 |
Why?
|
| Cell Survival | 2 | 2017 | 945 | 0.130 |
Why?
|
| Pancreatic Neoplasms | 1 | 2020 | 218 | 0.130 |
Why?
|
| Germ Cells | 1 | 2017 | 74 | 0.130 |
Why?
|
| Membrane Glycoproteins | 2 | 2009 | 224 | 0.130 |
Why?
|
| Disease Progression | 6 | 2014 | 667 | 0.130 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 37 | 0.130 |
Why?
|
| Drosophila Proteins | 1 | 2018 | 188 | 0.130 |
Why?
|
| Genes, BRCA1 | 1 | 2016 | 19 | 0.130 |
Why?
|
| Multigene Family | 1 | 2016 | 105 | 0.120 |
Why?
|
| Integrin alpha5 | 1 | 2016 | 2 | 0.120 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 423 | 0.120 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2016 | 10 | 0.120 |
Why?
|
| Magnesium Compounds | 1 | 2016 | 2 | 0.120 |
Why?
|
| Survival Rate | 2 | 2014 | 355 | 0.120 |
Why?
|
| Cell Line | 3 | 2018 | 1410 | 0.120 |
Why?
|
| Silicon Compounds | 1 | 2016 | 7 | 0.120 |
Why?
|
| Genealogy and Heraldry | 1 | 2015 | 5 | 0.120 |
Why?
|
| Skin | 1 | 2017 | 187 | 0.120 |
Why?
|
| Germany | 1 | 2015 | 26 | 0.120 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 80 | 0.120 |
Why?
|
| Molybdenum | 2 | 2022 | 22 | 0.120 |
Why?
|
| Cytokines | 4 | 2020 | 678 | 0.120 |
Why?
|
| Spectrometry, X-Ray Emission | 1 | 2015 | 20 | 0.120 |
Why?
|
| RNA, Small Interfering | 4 | 2018 | 436 | 0.120 |
Why?
|
| Transplantation, Heterologous | 2 | 2012 | 98 | 0.120 |
Why?
|
| Oregon | 1 | 2015 | 64 | 0.120 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 449 | 0.120 |
Why?
|
| Geology | 1 | 2015 | 6 | 0.120 |
Why?
|
| Interferon-gamma | 2 | 2015 | 269 | 0.120 |
Why?
|
| Treatment Outcome | 3 | 2016 | 1604 | 0.110 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2015 | 184 | 0.110 |
Why?
|
| Weather | 1 | 2015 | 13 | 0.110 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2015 | 159 | 0.110 |
Why?
|
| Retrospective Studies | 4 | 2016 | 2544 | 0.110 |
Why?
|
| Proteomics | 2 | 2020 | 378 | 0.110 |
Why?
|
| New York | 1 | 2015 | 93 | 0.110 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2015 | 95 | 0.110 |
Why?
|
| Cell Adhesion | 2 | 2012 | 238 | 0.110 |
Why?
|
| Cell Shape | 1 | 2013 | 42 | 0.100 |
Why?
|
| Receptors, Androgen | 1 | 2014 | 144 | 0.100 |
Why?
|
| Micronutrients | 1 | 2014 | 45 | 0.100 |
Why?
|
| Blotting, Southern | 2 | 2005 | 68 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2010 | 51 | 0.100 |
Why?
|
| Risk Factors | 3 | 2011 | 3994 | 0.100 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 98 | 0.100 |
Why?
|
| Fowlpox virus | 1 | 2013 | 2 | 0.100 |
Why?
|
| Syndrome | 1 | 2013 | 73 | 0.100 |
Why?
|
| beta Catenin | 1 | 2013 | 78 | 0.100 |
Why?
|
| Cadherins | 1 | 2013 | 102 | 0.100 |
Why?
|
| Lymph Nodes | 1 | 2013 | 74 | 0.100 |
Why?
|
| Spleen | 1 | 2013 | 204 | 0.090 |
Why?
|
| Mice, SCID | 4 | 2017 | 158 | 0.090 |
Why?
|
| Models, Biological | 2 | 2008 | 712 | 0.090 |
Why?
|
| Selenium | 1 | 2014 | 155 | 0.090 |
Why?
|
| North Dakota | 1 | 2011 | 2 | 0.090 |
Why?
|
| Transportation | 1 | 2011 | 27 | 0.090 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2011 | 11 | 0.090 |
Why?
|
| Blotting, Western | 5 | 2014 | 883 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 2 | 2014 | 1869 | 0.080 |
Why?
|
| Genetic Loci | 1 | 2011 | 104 | 0.080 |
Why?
|
| HMGB Proteins | 1 | 2010 | 2 | 0.080 |
Why?
|
| Transcription, Genetic | 1 | 2013 | 592 | 0.080 |
Why?
|
| Adenosine Diphosphate Ribose | 1 | 2010 | 4 | 0.080 |
Why?
|
| Poly Adenosine Diphosphate Ribose | 1 | 2010 | 3 | 0.080 |
Why?
|
| Disease Models, Animal | 4 | 2017 | 1596 | 0.080 |
Why?
|
| Cells | 1 | 2010 | 9 | 0.080 |
Why?
|
| Enzyme Activation | 2 | 2014 | 462 | 0.080 |
Why?
|
| Family Health | 2 | 2008 | 55 | 0.080 |
Why?
|
| Precancerous Conditions | 1 | 2011 | 83 | 0.080 |
Why?
|
| Vaccination | 1 | 2013 | 355 | 0.080 |
Why?
|
| Necrosis | 1 | 2010 | 54 | 0.080 |
Why?
|
| Lectins | 2 | 2012 | 19 | 0.080 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2010 | 79 | 0.080 |
Why?
|
| Gene Expression Regulation | 2 | 2013 | 1070 | 0.080 |
Why?
|
| Air Pollutants | 1 | 2011 | 130 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-fos | 2 | 2007 | 83 | 0.080 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2009 | 52 | 0.080 |
Why?
|
| Hydrogen Peroxide | 1 | 2010 | 190 | 0.080 |
Why?
|
| Inflammation Mediators | 1 | 2010 | 140 | 0.070 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2008 | 7 | 0.070 |
Why?
|
| RNA, Antisense | 1 | 2008 | 18 | 0.070 |
Why?
|
| Blotting, Northern | 1 | 2008 | 150 | 0.070 |
Why?
|
| Ribonucleases | 1 | 2008 | 32 | 0.070 |
Why?
|
| Virus Integration | 1 | 2008 | 65 | 0.070 |
Why?
|
| Capsid Proteins | 1 | 2008 | 76 | 0.070 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2008 | 62 | 0.070 |
Why?
|
| MAP Kinase Kinase 5 | 1 | 2007 | 4 | 0.070 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2007 | 19 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 440 | 0.070 |
Why?
|
| Reactive Oxygen Species | 1 | 2010 | 532 | 0.070 |
Why?
|
| Compensation and Redress | 1 | 2007 | 3 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2025 | 1600 | 0.060 |
Why?
|
| Public Health Administration | 1 | 2007 | 26 | 0.060 |
Why?
|
| Patient Selection | 1 | 2009 | 205 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 1 | 2008 | 515 | 0.060 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2006 | 26 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 220 | 0.060 |
Why?
|
| Transcription Factor AP-1 | 1 | 2006 | 34 | 0.060 |
Why?
|
| Metaphase | 1 | 2006 | 7 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2006 | 22 | 0.060 |
Why?
|
| Cross Reactions | 1 | 2006 | 87 | 0.060 |
Why?
|
| Chromosomes, Human | 1 | 2006 | 37 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 526 | 0.060 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2006 | 95 | 0.060 |
Why?
|
| Sialoglycoproteins | 1 | 2005 | 14 | 0.060 |
Why?
|
| Transcriptional Activation | 1 | 2006 | 173 | 0.060 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2006 | 166 | 0.060 |
Why?
|
| Genome, Viral | 1 | 2006 | 119 | 0.060 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2006 | 113 | 0.060 |
Why?
|
| Endothelial Cells | 1 | 2008 | 329 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2012 | 458 | 0.060 |
Why?
|
| RNA Interference | 1 | 2006 | 247 | 0.060 |
Why?
|
| Carcinogenicity Tests | 1 | 2004 | 5 | 0.060 |
Why?
|
| Bone Marrow | 1 | 2005 | 35 | 0.060 |
Why?
|
| Disease Outbreaks | 1 | 2006 | 175 | 0.060 |
Why?
|
| Aldehyde Reductase | 1 | 2024 | 16 | 0.060 |
Why?
|
| Pleural Effusion | 2 | 2016 | 8 | 0.050 |
Why?
|
| Asbestos, Amphibole | 1 | 2024 | 1 | 0.050 |
Why?
|
| Radiography | 1 | 2004 | 71 | 0.050 |
Why?
|
| ROC Curve | 3 | 2012 | 159 | 0.050 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2004 | 2 | 0.050 |
Why?
|
| Glycolysis | 1 | 2024 | 71 | 0.050 |
Why?
|
| DNA Primers | 1 | 2005 | 294 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2005 | 94 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2004 | 23 | 0.050 |
Why?
|
| Staining and Labeling | 1 | 2004 | 107 | 0.050 |
Why?
|
| Oncogenes | 1 | 2004 | 44 | 0.050 |
Why?
|
| Viral Vaccines | 1 | 2004 | 37 | 0.050 |
Why?
|
| Ependymoma | 1 | 2003 | 1 | 0.050 |
Why?
|
| Choroid Plexus Neoplasms | 1 | 2003 | 1 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2010 | 518 | 0.050 |
Why?
|
| Occupational Diseases | 1 | 2004 | 53 | 0.050 |
Why?
|
| Genetic Techniques | 1 | 2003 | 14 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2011 | 310 | 0.050 |
Why?
|
| Receptor, Notch1 | 1 | 2003 | 16 | 0.050 |
Why?
|
| Glucose | 1 | 2024 | 244 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2002 | 12 | 0.050 |
Why?
|
| Chromosomes, Human, X | 1 | 2002 | 23 | 0.050 |
Why?
|
| Translocation, Genetic | 1 | 2002 | 40 | 0.050 |
Why?
|
| Models, Molecular | 1 | 2006 | 876 | 0.050 |
Why?
|
| Mammals | 1 | 2023 | 112 | 0.050 |
Why?
|
| Lithium | 1 | 2022 | 31 | 0.050 |
Why?
|
| Water Supply | 1 | 2022 | 60 | 0.050 |
Why?
|
| Cadmium | 1 | 2022 | 56 | 0.050 |
Why?
|
| Enzyme Induction | 1 | 2002 | 52 | 0.050 |
Why?
|
| Drug Contamination | 1 | 2002 | 11 | 0.050 |
Why?
|
| Gene Dosage | 2 | 2014 | 75 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2008 | 368 | 0.050 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2002 | 22 | 0.050 |
Why?
|
| Gene Deletion | 1 | 2002 | 168 | 0.040 |
Why?
|
| Lung Diseases | 1 | 2002 | 63 | 0.040 |
Why?
|
| Manganese | 1 | 2022 | 92 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2005 | 403 | 0.040 |
Why?
|
| Butadienes | 2 | 2011 | 29 | 0.040 |
Why?
|
| Nitriles | 2 | 2011 | 81 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2003 | 536 | 0.040 |
Why?
|
| Time Factors | 3 | 2010 | 1857 | 0.040 |
Why?
|
| Biological Specimen Banks | 1 | 2019 | 28 | 0.040 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2018 | 15 | 0.040 |
Why?
|
| Adolescent | 2 | 2010 | 6081 | 0.040 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2018 | 32 | 0.040 |
Why?
|
| Consensus | 1 | 2018 | 48 | 0.040 |
Why?
|
| Immunoprecipitation | 1 | 2018 | 127 | 0.040 |
Why?
|
| Ubiquitination | 1 | 2018 | 62 | 0.040 |
Why?
|
| Immunoblotting | 1 | 2018 | 181 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2018 | 196 | 0.040 |
Why?
|
| Hawaii | 1 | 2024 | 2011 | 0.030 |
Why?
|
| Drosophila | 1 | 2018 | 152 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 51 | 0.030 |
Why?
|
| Protein Phosphatase 2 | 1 | 2017 | 26 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2020 | 1035 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2018 | 346 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2008 | 575 | 0.030 |
Why?
|
| Acetylation | 1 | 2016 | 107 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 287 | 0.030 |
Why?
|
| Multiprotein Complexes | 1 | 2015 | 56 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 186 | 0.030 |
Why?
|
| Brain | 1 | 2003 | 1472 | 0.030 |
Why?
|
| Granzymes | 1 | 2015 | 19 | 0.030 |
Why?
|
| Immunodominant Epitopes | 1 | 2015 | 29 | 0.030 |
Why?
|
| Antibody Formation | 1 | 2015 | 76 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2015 | 32 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 95 | 0.030 |
Why?
|
| Transgenes | 1 | 2015 | 65 | 0.030 |
Why?
|
| Immunization | 1 | 2015 | 94 | 0.030 |
Why?
|
| Hela Cells | 1 | 2015 | 376 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2015 | 165 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2015 | 74 | 0.030 |
Why?
|
| Histones | 1 | 2015 | 197 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2015 | 132 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2015 | 249 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2012 | 87 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2014 | 457 | 0.020 |
Why?
|
| Chromosomes, Mammalian | 1 | 2011 | 18 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 114 | 0.020 |
Why?
|
| Fibrosarcoma | 1 | 2010 | 8 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2010 | 27 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2010 | 224 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2010 | 256 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 100 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2009 | 64 | 0.020 |
Why?
|
| Carcinoma | 1 | 2010 | 108 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 411 | 0.020 |
Why?
|
| Neutrophils | 1 | 2010 | 145 | 0.020 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2009 | 74 | 0.020 |
Why?
|
| Drug Carriers | 1 | 2010 | 174 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2009 | 17 | 0.020 |
Why?
|
| Transfection | 1 | 2010 | 532 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2009 | 116 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2008 | 10 | 0.020 |
Why?
|
| Ceruloplasmin | 1 | 2008 | 15 | 0.020 |
Why?
|
| Palliative Care | 1 | 2009 | 61 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2008 | 53 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 465 | 0.020 |
Why?
|
| Rana pipiens | 1 | 2008 | 63 | 0.020 |
Why?
|
| Pleural Cavity | 1 | 2008 | 1 | 0.020 |
Why?
|
| Thoracotomy | 1 | 2008 | 5 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2008 | 95 | 0.020 |
Why?
|
| Diet | 1 | 2014 | 826 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 236 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 183 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2009 | 375 | 0.020 |
Why?
|
| Community-Based Participatory Research | 1 | 2010 | 352 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 518 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2007 | 986 | 0.010 |
Why?
|
| Databases, Genetic | 1 | 2004 | 103 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2005 | 490 | 0.010 |
Why?
|
| RNA, Complementary | 1 | 2004 | 10 | 0.010 |
Why?
|
| Recurrence | 1 | 2004 | 152 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2004 | 223 | 0.010 |
Why?
|
| Pleural Diseases | 1 | 2002 | 3 | 0.010 |
Why?
|
| HLA Antigens | 1 | 2002 | 27 | 0.010 |
Why?
|
| Prevalence | 1 | 2002 | 1612 | 0.010 |
Why?
|